The Androgen Axis in Recurrent Prostate Cancer

Clinical Cancer Research

Volumn 10, Issue 2, 2004, Pages 440-448

  Mohler, James L ^a,b,c,d   Gregory, Christopher W ^a   Ford III, Harris ^a,b   Kim, Desok ^a   Weaver, Catharina M ^a   Petrusz, Peter ^b   Wilson, Elizabeth M ^a,b   French, Frank S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; FLUTAMIDE; MONOCLONAL ANTIBODY; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ARTICLE; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RADIOIMMUNOASSAY; RECURRENT CANCER; RECURRENT PROSTATE CANCER; TISSUE LEVEL;

AGED; AGED, 80 AND OVER; ANDROGENS; ANDROSTENEDIONE; ANTIBODIES, MONOCLONAL; CELL NUCLEUS; DEHYDROEPIANDROSTERONE; DIHYDROTESTOSTERONE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, VIDEO; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOIMMUNOASSAY; RECEPTORS, ANDROGEN; RECURRENCE;

EID: 0842311632     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1146-03     Document Type: Article

References (66)

1. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., and Thun, M. J. Cancer statistics 2003. CA. Cancer J. Clin., 53: 5-26, 2003.
2. Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J., Petros, J. A., and Andriole, G. L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med., 324: 1156-1161, 1991.
3. Huggins, C., and Hodges, C. V. Studies on prostatic carcinoma; effect of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1: 293-297, 1941.
4. Feldman, B. J., and Feldman, D. The development of androgen-independent prostate cancer. Nature Rev., 1: 34-45, 2001.
5. Gelmann, E. P. Molecular biology of the androgen receptor. J. Clin. Oncol., 20: 3001-3015, 2002.
6. Grossman, M. E., Huang, H., and Tindall, D. J. Androgen receptor signaling in androgen refractory prostate cancer. J. Natl. Cancer Inst., 93: 1687-1697, 2001.
7. Sadi, M. V., and Barrack, E. R. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Cancer (Phila.), 71: 2574-2580, 1993.
8. Takeda, H., Akakura, K., Masai, M., Akimoto, S., Yatani, R., and Shimazaki, J. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer (Phila.), 77: 934-940, 1996.
9. Tilley, W. D., Lim-Tio, S. S., Horsfall, D. J., Aspinall, J. O., Marshall, V. R., and Skinner, J. M. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: Measurement by color video image analysis. Cancer Res., 54: 4096-4102, 1994.
10. Prins, G. S., Sklarew, R. J., and Pertschuk, L. P. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J. Urol., 159: 641-649, 1998.
11. van der Kwast, T. H., Schalken, J., Ruizeveld de Winter, J. A., van Vroonhoven, C. C., Mulder, E., Boersma, W., and Trapman, J. Androgen receptors in endocrine therapy-resistant human prostate cancer. Int. J. Cancer, 48: 189-193, 1991.
12. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., and Kallioniemi, O. P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9: 401-406, 1995.
13. Takahashi, H., Furusato, M., Allsbrook, W. C., Jr., Nishii, H., Wakui, S., Barrett, J. C., and Boyd, J. Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res., 55: 1621-1624, 1995.
14. Tilley, W. D., Buchanan, G., Hickey, T. E., and Bentel, J. M. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res., 2: 277-285, 1996.
15. Ruizeveld de Winter, J. A., Janssen, P. J., Sleddens, H. M., Verleun-Mooijman, M. C., Trapman, J., Brinkmann, A. O., Santerse, A. B., Schroder, F. H., and van der Kwast, T. H. Androgen receptor status in localized and locally progressive hormone refractory prostate cancer. Am. J. Pathol., 144: 735-746, 1994.
16. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med., 332: 1393-1398, 1995.
17. Culig, Z., Hobisch, A., Cronauer, M. V., Cato, A. C., Hittmair, A., Radmayr, C., Eberle, J., Bartsch, G., and Klocker, H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol., 7: 1541-1550, 1993.
18. Tan, J-A., Sharief, Y., Hamil, K. G., Gregory, C. W., Zang, D. Y., Sar, M., Gumerlock, P. H., DeVere White, R. W., Pretlow, T. G., Harris, S. E., Wilson, E. M., Mohler, J. L., and French, F. S. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol. Endocrinol., 11: 450-459, 1997.
19. Peterziel, H., Culig, Z., Stober, J., Hobisch, A., Radmayr, C., Bartsch, G., Klocker, H., and Cato, A. C. Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Int. J. Cancer, 63: 544-550, 1995.
20. Shi, X., Ma, A., Xia, L., Kung, H., and de Vere White, R. W. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res., 62: 1496-1502, 2002.
21. Kim, D., Gregory, C. W., Smith, G. J., and Mohler, J. L. Immunohistochemical quantitation of androgen receptor expression using color video image analysis. Cytometry, 35: 2-10, 1999.
22. Gaston, K. E., Ford, O. H., III, Singh, S., Gregory, C. W., Weyel, D. E., Smith, G. J., and Mohler, J. L. A novel method for analysis of the androgen receptor. Curr. Urol. Rep., 3: 67-74, 2002.
23. Kim, D., Gregory, C. W., French, F. S., Smith, G. J., and Mohler, J. L. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. Am. J. Pathol., 160: 219-226, 2002.
24. Gregory, C. W., Johnson, R. T., Presnell, S. C., Mohler, J. L., and French, F. S. Androgen receptor regulation of G1 cyclin and cyclin dependent kinase function in the CWR22 human prostate cancer xenograft. J. Andrology, 22: 537-548, 2001.
25. Gregory, C. W., Kim, D., Ye, P., D'Ercole, A. J., Pretlow, T. G., Mohler, J. L., and French, F. S. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft. Endocrinology, 140: 2372-2381, 1999.
26. Gregory, C. W., Hamil, K. G., Kim, D., Hall, S. H., Pretlow, T. G., Mohler, J. L., and French, F. S. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res., 58: 5718-5724, 1998.
27. Sadar, M. D., Hussein, M., and Bruchovsky, N. Prostate cancer: Molecular biology of early progression to androgen independence. Endocr. Relat. Cancer, 6: 487-502, 1999.
28. Mohler, J. L., Morris, T. L., Ford, O. H., III, Alvey, R. F., Sakamoto, C., and Gregory, C. W. Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate, 51: 247-255, 2002.
29. Mousses, S., Wagner, U., Chen, Y., Kim, J. W., Bubendorf, L., Bittner, M., Pretlow, T., Elkahloun, A. G., Trepel, J. B., and Kallioniemi, O. P. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene, 20: 6718-6723, 2001.
30. Stewart, R. J., Panigraphy, D., Flynn, E., and Folkman, J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J. Urol., 165: 688-693, 2001.
31. Miyake, H., Pollak, M., and Gleave, M. E. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res., 60: 3058-3064, 2000.
32. de Vere White, R., Meyers, F., Chi, S-G., Chamberlain, S., Siders, D., Lee, F., Stewart, S., and Gumerlock, P. H. Human androgen receptor expression in prostate cancer following androgen ablation. Eur. Urol., 31: 1-6, 1997.
33. Culig, Z., Hoffmann, J., Erdel, M., Eder, I. E., Hobisch, A., Hittmair, A., Bartsch, G., Utermann, G., Schneider, M. R., Parczyk, K., and Klocker, H. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br. J. Cancer, 81: 242-251, 1999.
34. Gregory, C. W., Johnson, R. T., Mohler, J. L., French, F. S., and Wilson, E. M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res., 61: 2892-2898, 2001.
35. Forti, G., Salerno, R., Moneti, G., Zoppi, S., Fiorelli, G., Marinoni, T., Natali, A., Costantini, A., Serio, M., Martini, L., and Motta, M. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5α-reductase activity and androgen receptor content. J. Clin. Endocrinol. Metab., 68: 461-468, 1989.
36. Shibata, Y., Ito, K., Suzuki, K., Nakano, K., Fukabori, Y., Suzuki, R., Kawabe, Y., Honma, S., and Yamanaka, H. Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate, 42: 45-55, 2000.
37. Harper, M. E., Pike, A., Peeling, W. B., and Griffiths, K. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J. Endocrinol., 60: 117-125, 1974.
38. Belanger, B., Belanger, A., Labrie, F., Dupont, A., Cusan, L., and Monfette, G. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: Unique importance of extratesticular androgens in men. J. Steroid Biochem., 32: 695-698, 1989.
39. Hammond, G. L. Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues. J. Endocrinol., 78: 7-19, 1978.
40. Geller, J., Albert, J., Loza, D., Geller, S., Stoeltzing, W., and de la Vega, D. DHT concentrations in human prostate cancer tissue. J. Clin. Endocrinol. Metab., 46: 440-444, 1978.
41. Geller, J., Albert, J., and Loza, D. Steroid levels in cancer of the prostate. Markers of tumor differentiation and adequacy of antiandrogen therapy. J. Steroid Biochem., 11: 631-636, 1979.
42. Dunn, J. F., Nisula, B. C., and Rodbard, D. Transport of steroid hormones: Binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid binding globulin in human plasma. J. Clin. Endocrinol. Metab., 53: 58-68, 1981.
43. Bartsch, G. W., Klein, H., Schiemann, U., Bauer, H. W., and Voigt, K. D. Enzymes of androgen formation and degradation in the human prostate. Ann. N. Y. Acad. Sci., 595: 53-66, 1990.
44. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet, 346: 265-269, 1995.
45. Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., Jr., Bueschen, A. J., and Lowe, B. A. Bilateral orchiectomy with or without flutamide for the treatment of patients with stage D2 prostate cancer. N. Eng. J. Med., 339: 1036-1042, 1998.
46. Imperato-McGinley, J., Guerrero, L., Gautier, T., and Peterson, R. E. Steroid 5-α-reductase deficiency in man: an inherited form of pseudohermaphroditism. Science (Wash. DC), 186: 1213-1215, 1974.
47. Wilson, J. D., Griffin, J. E., and Russell, D. W. Steroid 5-α-reductase 2 deficiency. Endocrine Rev., 14: 577-596, 1993.
48. Bruchovsky, N., and Wilson, J. D. The conversion of testosterone to 5-α-andorstan-17-β-ol-3-one by rat prostate in vivo and in vitro. J. Biol. Chem., 243: 2012-2021, 1968.
49. De Larminat, M. A., Rennie, P. S., and Bruchovsky, N. Radioimmunoassay measurements of nuclear dihydrotestosterone in rat prostate. Biochem. J., 200: 465-474, 1981.
50. Wilson, E. M., and French, F. S. Binding properties of androgen receptors: Evidence for identical receptors in rat testis, epididymis, and prostate. J. Biol. Chem., 251: 5620-5629, 1976.
51. Simard, J., Luthy, I., Guay, J., Belanger, A., and Labrie, F. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol. Cell. Endocrinol., 44: 261-270, 1986.
52. Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., III, Mohler, J. L., French, F. S., and Wilson, E. M. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res., 61: 4315-4319, 2001.
53. Dai, J., Shen, R., Sumitomo, M., Stahl, R., Navarro, D., Gershengorn, M. C., and Nanus, D. M. Synergistic activation of the androgen receptor by bombesin and low-dose androgen. Clin. Cancer Res., 8: 2399-2405, 2002.
54. Ueda, T., Bruchovsky, N., and Sadar, M. D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem., 277: 7076-7085, 2002.
55. Ueda, T., Mawji, N. R., Bruchosvsky, N., and Sadar, M. D. Ligand-independent activation of the androgen receptor by IL-6 and the role of the coactivator SRC-I in prostate cancer cells. J. Biol. Chem., 277: 38087-38094, 2002.
56. Craft, N., Shostak, Y., Carey, M., and Sawyers, C. L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med., 5: 280-285, 1999.
57. Abreu-Martin, M. T., Chari, A., Palladino, A. A., Craft, N. A., and Sawyers, C. L. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol. Cell. Biol. 19: 5143-5154, 1999.
58. Yeh, S., Lin, H. K., Kang, H. Y., Thin, T. H., Lin, M. F., and Chang, C. From HER-2/neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA, 96: 5458-5463, 1999.
59. Stege, R., Tribukait, B., Lundh, B., Carlstrom, K., Pousette, A., and Hasenson, M. Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma. J. Urol., 148: 833-837, 1992.
60. Yang, Y., Chisholm, G. D., and Habib, F. K. The distribution of PSA, cathepsin-D and pS2 in BPH and cancer of the prostate. Prostate, 21: 201-208, 1992.
61. Hryb, D. J., Nakhla, A. M., Kahn, S. M., St George, J., Levy, N. C., Romas, N. A., and Rosner, W. Sex hormone-binding globulin in the human prostate is locally synthesized and may act as an autocrine/paracrine effector. J. Biol. Chem., 277: 26618-26222, 2002.
62. Ding, V. D., Moller, D. E., Feeney, W. P., Didolkar, V., Nakhla, A. M., Rhodes, L., Rosner, W., and Smith, R. G. Sex hormone-binding globulin mediates prostate androgen receptor action via a novel signaling pathway. Endocrinology, 139: 213-218, 1998.
63. Rosner, W. The functions of corticosteroid-binding globulin and sex hormone-binding globulin: recent advances. Endocr. Rev., 11: 80-91, 1990.
64. Hryb, D. J., Khan, M. S., Romas, N. A., and Rosner, W. The control of the interaction of sex hormone-binding globulin with its receptor by steroid hormones. J. Biol. Chem., 265: 6048-6054, 1990.
65. Hsing, A. W., Reichardt, J. K. V., and Stanczyk, F. Z. Hormones and prostate cancer: Current perspectives and future directions. Prostate, 52: 213-235, 2002.
66. Zegarra-Moro, O. L., Schmidt, L. J., Huang, H., and Tindall, D. J. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res., 62: 1008-1013, 2002.